Sorrento Therapeutics, Inc. SRNE · Stock Open Sorrento Therapeutics, Inc. in new tab
Sorrento Therapeutics, Inc. Analysis (SRNE)
Is Sorrento Therapeutics, Inc. a good investment? Sorrento Therapeutics, Inc. (SRNE) is currently trading at 0.000400 USD.
Earnings Schedule: Sorrento Therapeutics, Inc. is expected to release its next earnings report on Nov. 6, 2026.
Investor FAQ
Does Sorrento Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Sorrento Therapeutics, Inc.?
Sorrento Therapeutics, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 6, 2026. The company currently has a trailing EPS of -0.07.
Company Profile
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are used for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases treatment. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.
| Split Date | Split Ratio to 1 |
|---|---|
| March 16, 2007 | 1:20 |
| Oct. 7, 2008 | 1:10 |
| Aug. 1, 2013 | 1:25 |
Community Discussion